drugset / Trial / NCT02579928

Ketamine Infusion for Adolescent Depression and Anxiety

NCT02579928

RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to determine the tolerability and short-term efficacy of a single ketamine infusion for the treatment of adolescents with 1) medication-refractory major depressive disorder (MDD) and/or 2) medication-refractory anxiety disorders (social anxiety disorder, panic disorder, generalized anxiety disorder and/or separation anxiety disorder).

Timeline

Start
2015-10
Primary completion
2018-09-28
Completion
2019-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.5 mg/kg Intravenous
Subject Midazolam Small molecule 0.045 mg/kg Intravenous